Form 4: Capricor Therapeutics Director Exercises Stock Options

Director David B. Musket exercised stock options to acquire 34,000 shares of Capricor Therapeutics common stock at $1.39 per share on August 7, 2024.

Summary

• On August 7, 2024, David B. Musket, a director of Capricor Therapeutics, Inc., exercised stock options to acquire 34,000 shares of common stock at a price of $1.39 per share.
• Following the transaction, Musket directly owns 81,692 shares of common stock.
• Musket also indirectly owns 7,096 shares held in an IRA.
• The exercised stock options were granted with an exercise price of $1.39 and expire on June 5, 2030.
• The options vested in monthly installments starting March 1, 2020.

Sentiment

Score: 5

Explanation: This is a neutral event. A director exercised stock options, which is a routine transaction. It doesn't necessarily indicate a positive or negative outlook for the company.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders, such as directors and officers, trade in their company's stock. This filing indicates a director's decision to exercise stock options, which could be seen as a sign of confidence in the company's future prospects, but it is a routine transaction.

Stakeholder Impact

• The exercise of stock options by a director could have a minor dilutive effect on existing shareholders.

Key Dates